BAM Logo

Special Haemostasis

EPTIS factsheet 580335 | Last revision 2020-12-02 | URL: https://www.eptis.bam.de/pts580335 https://www.eptis.bam.de/pts580335

PT provider
Based in Australia
Language(s) English
Remarks All the above test item distinctions are available as separate programs.
Product groups Human test material
Testing fields Medical analysis
Technical details
Test item Tested property Testing method
Plasma (lyophilised) activated protein C resistance (APCR) -
Apixaban (Anti Xa) -
Dabigatran (direct Thrombin Inhibitor) -
FVIII Inhibitor -
Factor XIII (Screen and Assay) -
Low Molecular Weight Heparin Monitoring -
Lupus Anticoagulant -
Tube with dried agonist PFA-100/200 analysis -
Plasma (lyophilised) Rivaroxaban (Anti Xa) -
Protein C -
Protein -
Antithrombin -
Unfractionated Heparin Monitoring -
Von Willebrand Factor -
Aims of the PT scheme
Target group of participants
Linked to specific legislation / standards
Additional, subsidiary aims
Number of participants
Accredited or otherwise reviewed by a 3rd party

Accredited by NATA on the basis of Accredited by NATA on the basis of Accredited by NATA on the basis of ISO/IEC 17043: 2010

Operation is commissioned / requested by
Fees and frequency
Participation fee Yes
Regularly operated Yes (Lupus Anticoagulant: 2 samples per survey/3 surveys, Other options: 2 samples per survey/2 surveys)
Year of first operation
Contact details of the PT provider
Provider Contact person
Suite 201/8 Herbert Street
St Leonards, 2065

Phone: (61 2) 9045 6000
Fax: (61 2) 9356 2003
Web: https://www.rcpaqap.com.au/ https://www.rcpaqap.com.au/
Mr Rhys Judd
Phone: (61 2) 9045 6000
Fax: (61 2) 9356 2003
Email: rhys.judd@rcpaqap.com.au rhys.judd@rcpaqap.com.au
If you find any mistakes please contact the responsible EPTIS coordinator in Australia, Ms Luminita Antin. Ms Luminita Antin.
Any questions or problems? Please contact us at eptis@bam.de.
Application version: 1.23-SNAPSHOT.20230502124635-7925ae379a631fc1ececff45d2921c8db38877d5